Those Who Invested in Prestige Consumer Healthcare (NYSE:PBH) Five Years Ago Are up 144%
Those Who Invested in Prestige Consumer Healthcare (NYSE:PBH) Five Years Ago Are up 144%
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. For example, the Prestige Consumer Healthcare Inc. (NYSE:PBH) share price has soared 144% in the last half decade. Most would be very happy with that. Also pleasing for shareholders was the 16% gain in the last three months. But this move may well have been assisted by the reasonably buoyant market (up 8.3% in 90 days).
任何股票(假设你不使用杠杆)的最大损失是你的资金的100%。但好的一面是,如果你以合适的价格购买一家高质量公司的股票,你可以获得超过100%的收益。例如,Prestige Consumer Healthcare Inc.(纽约证券交易所代码:PBH)的股价在过去五年中飙升了144%。大多数人会对此感到非常满意。同样令股东高兴的是过去三个月的16%的涨幅。但是,这一举措很可能得到了相当活跃的市场(90天内上涨8.3%)的推动。
Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.
让我们来看看长期的基本面,看看它们是否与股东的回报一致。
To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
引用巴菲特的话说:“船只将在世界各地航行,但Flat Earth Society将蓬勃发展。市场上的价格和价值之间将继续存在巨大差异...”通过比较每股收益(EPS)和一段时间内的股价变化,我们可以了解投资者对公司的态度是如何随着时间的推移而变化的。
Prestige Consumer Healthcare's earnings per share are down 1.6% per year, despite strong share price performance over five years. This was, in part, due to extraordinary items impacting earning in the last twelve months.
尽管五年来股价表现强劲,但Prestige Consumer Healthcare的每股收益每年下降1.6%。这在一定程度上是由于非同寻常的项目影响了过去十二个月的收入。
So it's hard to argue that the earnings per share are the best metric to judge the company, as it may not be optimized for profits at this point. Therefore, it's worth taking a look at other metrics to try to understand the share price movements.
因此,很难说每股收益是评判公司的最佳指标,因为目前每股收益可能还没有针对利润进行优化。因此,值得一看其他指标,以了解股价走势。
On the other hand, Prestige Consumer Healthcare's revenue is growing nicely, at a compound rate of 4.2% over the last five years. It's quite possible that management are prioritizing revenue growth over EPS growth at the moment.
另一方面,Prestige Consumer Healthcare的收入增长良好,在过去五年中复合增长率为4.2%。目前,管理层很有可能将收入增长置于每股收益增长之上。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
您可以在下图中看到收入和收入随时间推移而发生的变化(点击图表查看确切值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240326/0-6603abdab2af24cfeaf4851c683aa6ce-0-451b015077a6bc3f7d91328a1ddf6516.png/big)
Take a more thorough look at Prestige Consumer Healthcare's financial health with this free report on its balance sheet.
通过这份免费的资产负债表报告,更全面地了解Prestige Consumer Healthcare的财务状况。
A Different Perspective
不同的视角
Prestige Consumer Healthcare shareholders are up 15% for the year. But that was short of the market average. It's probably a good sign that the company has an even better long term track record, having provided shareholders with an annual TSR of 20% over five years. It may well be that this is a business worth popping on the watching, given the continuing positive reception, over time, from the market. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 2 warning signs we've spotted with Prestige Consumer Healthcare .
Prestige 消费者医疗保健股东今年上涨了15%。但这低于市场平均水平。这可能是一个好兆头,表明该公司的长期业绩记录甚至更好,在五年内为股东提供了20%的年股东总回报率。鉴于随着时间的推移,市场持续给予积极的欢迎,这很可能是一项值得关注的业务。尽管市场状况可能对股价产生的不同影响值得考虑,但还有其他因素更为重要。为此,你应该注意我们在Prestige Consumer Healthcare发现的两个警告信号。
Of course Prestige Consumer Healthcare may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
当然,Prestige Consumer Healthcare可能不是最好的买入股票。因此,您可能希望看到这批免费的成长股。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。